Exactech, Inc. (NASDAQ:EXAC) will announce its earnings results after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $0.24 per share for the quarter.
Exactech (NASDAQ:EXAC) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a return on equity of 7.39% and a net margin of 0.30%. The business’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.31 EPS. On average, analysts expect Exactech to post $1.29 EPS for the current fiscal year and $1.41 EPS for the next fiscal year.
Exactech, Inc. (NASDAQ EXAC) opened at 41.85 on Friday. The stock has a 50 day moving average price of $33.45 and a 200 day moving average price of $30.67. Exactech, Inc. has a 52 week low of $22.20 and a 52 week high of $42.55. The stock has a market cap of $600.46 million, a PE ratio of 804.81 and a beta of 1.01.
COPYRIGHT VIOLATION WARNING: “Exactech, Inc. (EXAC) Scheduled to Post Quarterly Earnings on Monday” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/29/exactech-inc-exac-scheduled-to-post-quarterly-earnings-on-monday.html.
EXAC has been the subject of several analyst reports. Robert W. Baird downgraded Exactech from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a research report on Monday, October 23rd. Gabelli reaffirmed a “buy” rating on shares of Exactech in a research report on Monday, July 31st. Sidoti downgraded Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd. BidaskClub raised Exactech from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, Zacks Investment Research downgraded Exactech from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. Exactech currently has a consensus rating of “Hold” and an average price target of $42.00.
In other news, Director Fern Watts sold 1,013 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $29.04, for a total value of $29,417.52. Following the completion of the sale, the director now owns 4,727 shares of the company’s stock, valued at $137,272.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 28.30% of the stock is owned by corporate insiders.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.